Umoja Biopharma to Participate in Upcoming Investor Conferences in September

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, today announced that company management will participate in the following upcoming investor conferences:

Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6^th, 2024 in New York, NY

• Format: Company Presentation and 1×1 meetings
• Presenter: Andrew Scharenberg, M.D., Co-Founder and Chief Executive Officer
• Date & Time: 09/06/24 at 12:20 p.m. ET

A live webcast of the company presentation can be accessed at this link.

UBS Virtual Biotechnology Private Company Symposium on Wednesday, September 18^th, 2024

• Format: 1×1 Meetings

About Umoja Biopharma
Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CART cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/.

Investors
Stephen Jasper
Gilmartin Group, LLC
[email protected]

Media  
Matt Wright
Real Chemistry
[email protected]

• Author
• Recent Posts

GlobeNewswire

GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Latest posts by GlobeNewswire (see all)

• ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX - September 18, 2024
• Shareholders that lost money on Extreme Networks, Inc. (EXTR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - September 18, 2024
• Shareholders of Outset Medical, Inc. Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – OM - September 18, 2024